EP2265254A2 - Formulation de suspension pour des adsorbants au carbone - Google Patents

Formulation de suspension pour des adsorbants au carbone

Info

Publication number
EP2265254A2
EP2265254A2 EP09720023A EP09720023A EP2265254A2 EP 2265254 A2 EP2265254 A2 EP 2265254A2 EP 09720023 A EP09720023 A EP 09720023A EP 09720023 A EP09720023 A EP 09720023A EP 2265254 A2 EP2265254 A2 EP 2265254A2
Authority
EP
European Patent Office
Prior art keywords
formulations
water
suspension formulation
carbon
adsorbents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09720023A
Other languages
German (de)
English (en)
Inventor
Olaf Behrend
Iris Heep
Nikolaus Kowollik
Dirk Mertin
Petra Ohage-Spitzlei
Bernard Schmidt
Wolfgang Wiehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of EP2265254A2 publication Critical patent/EP2265254A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the invention relates to a hydrous suspension formulation comprising a coarse-grained carbon adsorbent which is suitable for binding and removal of harmful substances from the gastrointestinal tract, and to a water-soluble or water-dispersible structuring agent and a humectant.
  • these activated carbons are used as dry granules.
  • this dry application form is only conditionally suitable because it does not mix homogeneously with dry foods.
  • the application to dry food is an essential prerequisite for the commercial success of such a product in animals.
  • a liquid or pasty formulation containing the adsorbent can be combined with any type of feed.
  • the most important requirements for such a formulation are that the adsorption properties are not unduly reduced and the palatability of the food or feedstuff is not restricted by the composition and consistency nor by the dose volume, even in the case of accidental overdosage or top dressing.
  • Formulation based on a water-soluble carrier which mixes with oral administration without problems with the aqueous media of the gastrointestinal tract and the adsorbent is rapidly distributed freely for the adsorption of toxins dissolved in the aqueous medium. good compatibility even with permanent administration
  • the invention relates to:
  • a hydrous suspension formulation comprising a coarse-grained carbon adsorbent, a humectant, and a water-soluble or water-dispersible structuring agent.
  • coarse-grained carbon adsorbents are meant here those having a diameter of at least 0.1 mm, preferably 0.1 to 1 mm, particularly preferably 0.1 to 0.8 mm, in particular 0.1 to 0.6 mm.
  • these adsorbents have a spherical shape, an ideal spherical shape is not necessarily feasible in practice, therefore, “spherical” particles should also be understood as meaning approximately spherical particles.
  • the carbon adsorbents used according to the invention preferably have a specific surface, determined by the BET method, of 700 m 2 / g or more, more preferably 800 m 2 / g or more.
  • the carbon adsorbents may have functional groups.
  • they may have acidic groups which are preferably present in a total amount of 0.30 to 1.20 meq / g, in particular 0.30 to 1.00 meq / g.
  • the adsorbents may have basic groups, which are preferably present in a total amount of 0.20 to 0.70 meq / g, in particular 0.30 to 0.60 meq / g.
  • the adsorbents may have phenolic hydroxyl groups, which are preferably present in a total amount of 0.20 to 0.70 meq / g.
  • the adsorbents may also have carboxyl groups.
  • the adsorbents contain functional groups, they preferably have acidic and basic functional groups, preferably 0.30 to 1.20 meq / g, in particular 0.30 to 1.00 meq / g of acidic groups and 0.20 to 0 , 70 meq / g, especially 0.30 to 0.60 meq / g of basic groups.
  • these have a total amount of 0.30 to 1.20 meq / g, in particular 0.30 to 1.00 meq / g of acidic groups and a total of 0.20 to 0.70 meq / g, especially 0.30 to 0.60 meq / g of basic groups, with 0.20 to 0.70 meq / g of phenolic hydroxyl groups and 0.15 meq / g or less of carboxyl groups.
  • the ratio (a: b) of the total amount of acidic groups (a) to the total amount of basic groups (b) is 0.40 to 2.5.
  • the value of [(b + c) -d] for the total amount of basic groups (b), the amount of phenolic hydroxyl groups (c) and the amount of carboxyl groups (d) is preferably 0.60 or more (amounts in meq / g).
  • the carbon adsorbents preferably have a pore volume of the pores with a diameter of 20 to 15 000 nm of 0.04 mL / g to 0.1 mL / g, preferably 0.05 mL / g to 0.1 mL / g.
  • the formulations according to the invention usually contain 10 to 80% m / V, preferably 20 to 60% m / V, particularly preferably 30 to 50% m / V carbon adsorbent.
  • % m / V mass of the respective ingredient in grams per 100 mL of the final formulation.
  • the formulations usually contain 1 to 95% m / V, preferably 5 to 60% m / V, more preferably 10 to 40% m / V water.
  • the humectant is usually liquid to viscous and water soluble.
  • Humectants are preferably used di- or trihydric alcohols having 2 to 10, preferably 3 to 6 carbon atoms, for example, glycerol, ethylene glycol, Diethylene glycol or propylene glycol. Preference is given to propylene glycol and in particular glycerol.
  • the humectant is usually contained in the formulations in an amount of 10 to 95% m / V, preferably 50 to 80% m / V.
  • the formulations according to the invention also contain a water-soluble or water-dispersible structuring agent, which generally forms a yield-limit gel structure in the suspension formulations. It was found that the addition of a structuring agent improves the stability, in particular the long-term stability of the formulations, which is not easy with the relatively coarse-grained adsorbent.
  • suitable structuring agents may be mentioned in particular: cellulose derivatives, such as. Methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, polymeric carbohydrates, such as. Xanthan gum, alginate, gum arabic, pectins; Polypeptides, such as. As gelatin, casein, and polyvinylpyrrolidone (PVP), ethyl acrylate and methyl methacrylate copolymers or polyacrylic acid and mixtures of such components.
  • PVP polyvinylpyrrolidone
  • the structuring agent is usually present in amounts of 0.2 to 15% m / V, preferably 0.5 to 10% m / V, particularly preferably 1 to 5% m / V. If a mixture of structuring agents is used, the above information refers to the total amount.
  • the formulation of the invention may contain other conventional pharmaceutical ingredients, such as.
  • food dyes and / or pigments such as titanium dioxide or iron oxide.
  • pigments are usually contained in amounts of 0.1 to 10% m / V, preferably 0.2 to 8% m / V.
  • the formulation may also contain conventional preservatives, such as. B. sorbic acid optionally in combination with ascorbic acid. Standard concentrations are used which are familiar to the expert, such as. From 0.01 to 1% m / V.
  • the formulations do not contain any preservatives, and are particularly preferred if they contain more than 30% m / V, preferably more than 40% m / V, in particular more than 50% m / V of humectant.
  • the formulations of the invention are liquid, preferably viscous, to a pasty consistency.
  • the formulations according to the invention preferably have viscosities of from 1 to 100 Pas, particularly preferably from 1 to 30 Pas, very particularly preferably from 5 to 20 Pas (measured at a shear rate of 25 s -1 .)
  • the formulations according to the invention are preferably characterized by pseudoplastic flow behavior Preferably, they also show thixotropy.
  • the formulations according to the invention preferably have yield points of from 10 to 500 Pa, in particular from 30 to 200 Pa.
  • formulations according to the invention can be prepared, for example, by adding the
  • Structurant and optionally pigments and other auxiliaries mixed in a mixture of humectant and water, dissolves or dispersed and then incorporated the carbonaceous adsorbent in the formulation base and distributed homogeneously.
  • the formulations according to the invention are generally suitable for use in humans and animals. Preferably, they are used in livestock and animal breeding in livestock, breeding, zoo, laboratory, experimental and hobby animals, especially in mammals.
  • the livestock and breeding animals include mammals such as e.g. Cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur animals such as e.g. Mink, chinchilla, raccoon, as well as birds such as e.g. Chickens, geese, turkeys, ducks, pigeons and ostriches.
  • mammals such as e.g. Cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur animals such as e.g. Mink, chinchilla, raccoon, as well as birds such as e.g. Chickens, geese, turkeys, ducks, pigeons and ostriches.
  • preferred farm animals are beef, sheep, pork and chicken.
  • Laboratory and experimental animals include dogs, cats, rabbits and rodents such as mice, rats, guinea pigs and golden hamsters.
  • the hobby animals include dogs, cats, horses, rabbits, rodents such as golden hamsters, guinea pigs, mice, reptiles, amphibians and birds for home and zoo keeping.
  • the formulations of the invention are used in pets, and most preferably in dogs and especially cats.
  • the application can be both prophylactic and therapeutic.
  • the formulations of the invention are usually and preferably administered orally. Furthermore, a rectal administration is possible.
  • the formulations according to the invention are administered orally with the feed; they can be applied to both wet and dry food, mixed in or even on top.
  • Examples include: hepatotoxic encephalitis, chronic aflatoxin intoxication, acute intoxication.
  • the formulations of the invention are usually dosed so that 0.05 to 4.0, preferably 0.1 to 0.4 grams of carbon adsorbent per kilogram of body weight and day are administered.
  • these are typically dosing volumes of 0.5 to 10 mL.
  • these are typically dosing volumes of 0.5 to 10 mL.
  • the invention also relates to aqueous formulations of the preferred and particularly preferred spherical carbon adsorbents mentioned above and in EP-A-1249241.
  • the formulations of the invention have a good palatability, for example, the palatability of dry cat food in the dose range 5 - 2O g AST-120 / kg feed is not adversely affected.
  • AST-120 is used in the prior art only as a dry granule. Suspension formulations or pastes, in particular with a high proportion of adsorbent, have not been described so far.
  • the following table contains the measured values for the adsorption capacity of AST-120 in various paste formulations in comparison with pure, dry granules:
  • the adsorption values of the target toxins are generally only about 2-3% and not more than 5% below the dry granule data for all the formulations investigated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

L'invention concerne une formulation de suspension aqueuse contenant un adsorbant au carbone grossier destiné à lier et éliminer des substances nocives dans le tractus gastro-intestinal, ainsi qu'un agent structurel soluble ou dispersible dans l'eau, et un agent humidifiant.
EP09720023A 2008-03-13 2009-02-28 Formulation de suspension pour des adsorbants au carbone Withdrawn EP2265254A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008014109A DE102008014109A1 (de) 2008-03-13 2008-03-13 Suspensionsformulierung für Kohlenstoff-Adsorbentien
PCT/EP2009/001450 WO2009112169A2 (fr) 2008-03-13 2009-02-28 Formulation de suspension pour des adsorbants au carbone

Publications (1)

Publication Number Publication Date
EP2265254A2 true EP2265254A2 (fr) 2010-12-29

Family

ID=40823009

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09720023A Withdrawn EP2265254A2 (fr) 2008-03-13 2009-02-28 Formulation de suspension pour des adsorbants au carbone

Country Status (17)

Country Link
US (1) US20110021641A1 (fr)
EP (1) EP2265254A2 (fr)
JP (1) JP2011513448A (fr)
KR (1) KR20100135760A (fr)
CN (1) CN101969925A (fr)
AR (1) AR070974A1 (fr)
AU (1) AU2009225055A1 (fr)
BR (1) BRPI0908576A2 (fr)
CA (1) CA2718142A1 (fr)
CL (1) CL2009000538A1 (fr)
DE (1) DE102008014109A1 (fr)
MX (1) MX2010008982A (fr)
PE (1) PE20091578A1 (fr)
TW (1) TW200950791A (fr)
UY (1) UY31692A (fr)
WO (1) WO2009112169A2 (fr)
ZA (1) ZA201006082B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012140421A (ru) 2010-02-23 2014-03-27 Да Волтерра Лекарственные формы для пероральной доставки адсорбентов в кишечник
JP5739659B2 (ja) * 2010-12-27 2015-06-24 アピ株式会社 腸内有害物質吸着剤及びその製造方法
ES2467566B1 (es) * 2012-12-12 2015-01-22 Lainco, S.A. Composición farmacéutica de carbón activado en suspensión

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917821A (en) * 1973-10-23 1975-11-04 Milton Manes Palatable activated carbon
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US6830753B2 (en) * 2001-04-11 2004-12-14 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP3522708B2 (ja) * 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
ATE357924T1 (de) 2002-11-01 2007-04-15 Kureha Corp Adsorptionsmittel für die orale verabreichung, mittel zur behandlung oder prävention von nierenerkrankungen und mittel zur behandlung oder prävention von lebererkrankungen
KR101135260B1 (ko) 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
JP2006273772A (ja) * 2005-03-30 2006-10-12 Japan Organo Co Ltd 経口投与薬及びその製造方法
FR2904238B1 (fr) * 2005-04-14 2010-10-29 Serb Procede de production de suspensions de produits finement pulverulents, moyen destine a cet effet et les compositions pharmaceutiques contenant ces produits finement pulverulents
WO2006123618A1 (fr) * 2005-05-16 2006-11-23 Kureha Corporation Inhibiteur du stress oxydatif
DE202005011296U1 (de) * 2005-07-18 2005-10-13 Trw Automotive Safety Systems Gmbh Gassackmodul
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009112169A2 *

Also Published As

Publication number Publication date
AR070974A1 (es) 2010-05-19
CN101969925A (zh) 2011-02-09
BRPI0908576A2 (pt) 2015-09-22
KR20100135760A (ko) 2010-12-27
CL2009000538A1 (es) 2010-03-19
WO2009112169A3 (fr) 2010-05-14
CA2718142A1 (fr) 2009-09-17
US20110021641A1 (en) 2011-01-27
ZA201006082B (en) 2011-10-26
AU2009225055A1 (en) 2009-09-17
WO2009112169A2 (fr) 2009-09-17
PE20091578A1 (es) 2009-10-28
TW200950791A (en) 2009-12-16
MX2010008982A (es) 2010-09-07
DE102008014109A1 (de) 2009-09-17
JP2011513448A (ja) 2011-04-28
UY31692A (es) 2009-11-10

Similar Documents

Publication Publication Date Title
DE69730991T2 (de) Alginsaure enthaltende enterischer ueberzug fuer eine orale zubereitung
DE3874393T2 (de) Kuegelchen zur gesteuerten freisetzung eines arzneistoffs.
DE60019805T2 (de) Verfahren zur herstellung von orthokieselsäure, nach dem verfahren hergestellte orthokieselsäure und ihre verwendung
DE68909409T2 (de) Heilmitteldosierung zur verabreichung an fische.
EP3195857B1 (fr) Utilisation d'un modulateur trp de prophylaxie et/ou d'atténuation de la tétanie d'herbage et/ou de la parésie post-partum chez les ruminants ou les tylopodes
DE69106656T2 (de) Tanninextrakt von Kastanienholz, Verfahren zu deren Herstellung und deren Verwendung.
DE68903858T2 (de) Orale mittel fuer wiederkaeuer.
DE2841668A1 (de) Medikiertes tierfutter auf basis lebermehl
EP1513500A2 (fr) Preparations pharmaceutiques pour administration orale, contenant des resines echangeuses d'ions chargees de principes actifs ainsi que des gelifiants a viscosite intrinseque comme epaississants
DE69214310T2 (de) Pranoprofen enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe
EP2265254A2 (fr) Formulation de suspension pour des adsorbants au carbone
DE69213009T2 (de) Langzeit-abgabesystem mit hydrophobischer anfangsdosis
DE3230292A1 (de) Teilchenfoermiges futterzusatzmittel fuer wiederkaeuer
CN105726523B (zh) 一种用于治疗动物螨病的药物组合物及其制备方法和应用
DE60003188T2 (de) Paracetamol und drotaverin enthaltende zusammensetzung
DE10134719A1 (de) Pharmazeutische Zubereitungen enthaltend wirkstoffbeladene Ionentauscherharze
DE69002865T2 (de) Orale Zubereitung.
DE69311394T2 (de) Arzneimittel verzögerter Wirkstoffabgabe
EP2253307B1 (fr) L-carnitine pour la supression de la cristallisation
HK1150150A (en) Suspension formula for carbon adsorbents
CN115530286A (zh) 一种在宠物饲料中应用的蜂胶粉及其制备方法
DE2655331A1 (de) Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
DE2637863A1 (de) Mittel zur bekaempfung von parasiten bei warmbluetlern und verfahren zu ihrer herstellung
CH685370A5 (de) Veterinäres Präparat.
EP1862163A1 (fr) L-carnitine pour la supression de la cristallisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

17Q First examination report despatched

Effective date: 20121211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130423